Trial 9L-17-13


PhI-92: (NCI 10075) A Phase 1B Study of KRT-232 (AMG-232) in Combination with Decitabine and Venetoclax in Acute Myeloid Leukemia

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Chemotherapy: Systemic
Randomized: No
USC Satellite Location: None
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Kevin Kelly, M.D.
Other Trial Staff:  Simbiso Peresuh, Coordinator, Suraj Chandwani, D.M., Ashot Minasyan, D.M., Christine Duran, Coordinator, Donna Fernando, Coordinator, Nelli Dimitrova, D.M., Hannah Trey, Coordinator, Sonny Tong, D.M., Adrianne Harding, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.